ELOVL1 (NM_022821) Human Tagged ORF Clone Lentiviral Particle

CAT#: RC200027L2V

Lenti ORF particles, ELOVL1 (mGFP-tagged) - Human ELOVL fatty acid elongase 1 (ELOVL1), 200ul, >10^7 TU/mL

Specifications

Product Data

• Type: Human Tagged ORF Clone Lentiviral Particle
• Tag: mGFP
• Symbol: ELOVL1
• Synonyms: CGI-88; IKSHD; Ssc1
• Mammalian Cell Selection: None
• Vector: pLenti-C-mGFP
• ACCN: NM_022821
• ORF Size: 837 bp
• Sequence Data:
  ORF Nucleotide Sequence

  The ORF insert of this clone is exactly the same as(RC200027).
• OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info
• OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene.

Reference Data

• RefSeq: NM_022821.2
• RefSeq Size: 1501 bp
• RefSeq ORF: 840 bp
• Locus ID: 64834
• UniProt ID: Q9BW60
• Cytogenetics: 1p34.2
• Domains: ELO
• Protein Families: Transmembrane
• MW: 32.5 kDa
• Gene Summary: Catalyzes the first and rate-limiting reaction of the four reactions that constitute the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids (VLCFAs) per cycle. Condensing enzyme that exhibits activity toward saturated and monounsaturated acyl-CoA substrates, with the highest activity towards C22:0 acyl-CoA. May participate in the production of both saturated and monounsaturated VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators. Important for saturated C24:0 and monounsaturated C24:1 sphingolipid synthesis. Indirectly inhibits RPE65 via production of VLCFAs.[UniProtKB/Swiss-Prot Function]